Additionally, healthcare expenditure on diabetes education programs is projected to reach USD 500 million by end of 2025 according to a report from the Diabetes Foundation of India
doi:10.1111/dom.14725 Aronne LJ, Sattar N, Horn DB, et al
Table 3 Results of a 52-week Monotherapy Trial in Adults with Type 2 Diabetes Mellitus a Figure 3 Mean HbA 1c for Adult Patients with Type 2 Diabetes Mellitus who Completed the 52-week Trial and for the Last Observation Carried Forward (LOCF, intent-to-treat) data at Week 52 (Monotherapy) Combination Therapy Add-on to Metformin In this 26-week trial, 1,091 adult patients with type 2 diabetes mellitus were randomized to liraglutide injection 0.6 mg, liraglutide injection 1.2 mg, liraglutide injection 1.8 mg, placebo, or glimepiride 4 mg (one-half of the maximal approved dose in the United States), all as add-on to metformin
Both are manageable
doi: 10.1056/NEJMc2106918 170 GaberySSalinasCGPaulsenSJAhnfelt-RnneJAlanentaloTBaqueroAFet al
Approved pharmaceutical formulations will become available through traditional medical channels, potentially reducing demand for research-grade products
